FIELD: biotechnology.
SUBSTANCE: bispecific antibody that binds to the human CEACAM5 carcinoembryonic antigen and human CD47, a method for producing a bispecific antibody, a method and a pharmaceutical composition for the treatment of cancer that expresses CEACAM5 are proposed.
EFFECT: bispecific antibodies combine high efficacy with low toxicity, low immunogenicity, and favorable pharmacokinetic properties.
10 cl, 21 dwg, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLUBLE CD3 STABLE PHARMACEUTICAL COMPOSITIONS | 2006 |
|
RU2426743C2 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
| OBTAINING MULTISPECIFIC MIXTURES OF ANTIBODIES AND METHODS OF USE THEREOF | 2018 |
|
RU2815826C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| MULTI-SPECIFIC OR BISPECIFIC MOLECULE (VERSIONS), METHOD FOR ELIMINATION OR DECREASING QUANTITY OF TARGET CELLS IN SUBJECT'S BODY, METHOD FOR TREATING PATHOGEN-INFECTED SUBJECT AND METHOD FOR SUBJECT'S VACCINATION | 1997 |
|
RU2201766C2 |
